tetano
Editor, Senior Moderator
J Pediatr Hematol Oncol
. 2020 Dec 23;Publish Ahead of Print.
doi: 10.1097/MPH.0000000000002036. Online ahead of print.
Diagnostic Considerations in H1N1 Influenza-induced Thrombotic Microangiopathy
Anthony Sabulski[SUP] 1 [/SUP], Edward J Nehus, Sonata Jodele, Kiersten Ricci
Affiliations
Abstract
Influenza virus can trigger atypical hemolytic uremic syndrome and present with complement-driven thrombotic microangiopathy (TMA). When administered promptly, complement-blocking therapies can spare organ injury and be lifesaving. However, diagnosing TMA in the setting of a severe viral infection can be challenging, as a significant overlap of symptoms and disease complications exists. This is particularly true in influenza virus infections and more recently, Coronavirus disease 2019 (COVID-19) infections. We present a 16-year-old male with H1N1 influenza-induced atypical hemolytic uremic syndrome who quickly improved with complement-blocking therapy, highlighting an urgent need to include TMA in the differential diagnosis of severe viral infections.
. 2020 Dec 23;Publish Ahead of Print.
doi: 10.1097/MPH.0000000000002036. Online ahead of print.
Diagnostic Considerations in H1N1 Influenza-induced Thrombotic Microangiopathy
Anthony Sabulski[SUP] 1 [/SUP], Edward J Nehus, Sonata Jodele, Kiersten Ricci
Affiliations
- PMID: 33369997
- DOI: 10.1097/MPH.0000000000002036
Abstract
Influenza virus can trigger atypical hemolytic uremic syndrome and present with complement-driven thrombotic microangiopathy (TMA). When administered promptly, complement-blocking therapies can spare organ injury and be lifesaving. However, diagnosing TMA in the setting of a severe viral infection can be challenging, as a significant overlap of symptoms and disease complications exists. This is particularly true in influenza virus infections and more recently, Coronavirus disease 2019 (COVID-19) infections. We present a 16-year-old male with H1N1 influenza-induced atypical hemolytic uremic syndrome who quickly improved with complement-blocking therapy, highlighting an urgent need to include TMA in the differential diagnosis of severe viral infections.